Replies to post #113900 on Biotech Values

[DewDiligence]

…we could see the progress slow down over the push it gives the FDA regarding biologics.

If ObamaCare were scrapped in its entirety, I presume that Congress would enact a new authorization for generic biologics with similar terms to the current law. The additional machinations could conceivably delay the approval and launch of the first FoB’s, however, so you’re correct to note this as a risk for investors.